CHICAGO — Gastroesophageal reflux disease (GERD) patients with incomplete symptom control even on the maximum dose of proton pump inhibitor (PPI) therapy have a new, less invasive option than surgery. EndoGastric Solutions (EGS; San Mateo, California) released new data at Digestive Disease Week (DDW) in Chicago that show most GERD patients who underwent the Transoral Incisionless Fundoplication (TIF) procedure with the EsophyX device continued to report complete elimination of all troublesome regurgitation and esophagitis for a full year after the procedure. Read More
